1 min read
Pharmacovigilance as a Regulatory System
In Brazil, pharmacovigilance is a core component of the regulatory framework governing medicines throughout their lifecycle.
Under the structure defined by ANVISA, companies are required to establish and maintain a pharmacovigilance system, including defined responsibilities, procedures for safety data collection and evaluation, adverse event reporting, and risk management activities
Rather than a standalone requirement, pharmacovigilance functions as an integrated system connecting post-market surveillance, regulatory compliance, and patient safety.
Key Components of the Pharmacovigilance Framework
The Brazilian pharmacovigilance system is built around several core elements:
- Continuous collection and evaluation of safety data
- Reporting of adverse events within defined timelines
- Maintenance of a pharmacovigilance system with clearly assigned responsibilities
- Implementation of risk minimization and communication measures
These components are not isolated activities—they form part of an ongoing process supporting regulatory oversight and decision-making.
Compliance Beyond Reporting
A common misconception is that pharmacovigilance compliance is limited to adverse event reporting alone.
In practice, compliance depends on the ability to maintain a functioning pharmacovigilance system, including:
- Internal processes for data collection and evaluation
- Defined roles and responsibilities
- System documentation and traceability
- Readiness to respond to regulatory inspections
This system-based approach means that gaps in structure or oversight can lead to compliance risks, even when reporting obligations are met.
An Evolving Regulatory Landscape
Pharmacovigilance requirements in Brazil continue to evolve, with recent regulatory developments reinforcing expectations around system robustness, data quality, and inspection readiness across pharmacovigilance processes.
For pharmaceutical companies, this reinforces the importance of maintaining not only compliance but also adaptability to evolving regulatory expectations.
Pharmacovigilance in Brazil is not a discrete regulatory task—it is an ongoing commitment to safety, oversight, and system integrity.
Meeting these expectations goes beyond reporting obligations. It depends on how consistently safety processes are structured, connected, and sustained over time.
What appears compliant at the surface can quickly reveal gaps when consistency, traceability, and system integrity are tested; this is where the difference between operational compliance and true regulatory readiness becomes visible.
Contact Freyr’s experts to explore how your pharmacovigilance strategy can be strengthened to meet evolving regulatory expectations in Brazil.
